熱門資訊> 正文

Crystem Pharma首席运营官辞职

2026-03-24 03:54

Crinetics Pharmaceuticals (CRNX) chief development and operating officer Jeff Knight will resign, effective around April 10, 2026.
His responsibilities and team will be reassigned to other members of the executive leadership team.

More on Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow
Crinetics Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Most oversold mid-cap healthcare stocks on Wall Street amid Middle East disruptions
Crinetics outlines $600M–$650M 2026 operating expense plan as PALSONIFY launch accelerates

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。